MITF has the ability to upregulate transcription of melanoma-promoting genes (e.g., CyclinD1, BCL2, c-MET) and also that of melanoma-repressing genes (e.g., p16 Ink4a , p21 Cip1 , DIAHP1). The gene discussed is CDKN2A; the disease is melanoma.